Podcasts about Weathers

Former MLB Pitcher Josh Towers and Scott Seidenberg break down the MLB slate of games for Memorial Day This special Memorial Day episode of The Inside Pitch features Scott Seidenberg and former MLB pitcher Josh Towers providing a comprehensive breakdown of the upcoming Monday baseball slate. The podcast focuses on travel dynamics, pitcher performances, betting angles, and how team momentum and logistics influence game outcomes. Central to the discussion is the “Sunday Night Fade”—a strategy of betting against teams that play Sunday night games and must travel before playing again on Monday. Scott cites a 6-1 record with this approach, spotlighting the Dodgers' travel from New York to Cleveland. Josh outlines how travel delays, postgame treatment, and media responsibilities—especially for players like Shohei Otani—can exhaust players, making them vulnerable in early Monday games. Josh and Scott discuss Otani's homer against Kodai Senga, noting it was the first Senga allowed since Opening Day. They analyze the Dodgers-Guardians matchup: Gavin Williams has a strong home record (3-1, 3.40 ERA), but struggles at night (5.09 ERA), while Yamamoto has a 1.00 ERA overall and has not yet pitched in a day game. Despite Yamamoto's strength, Josh is cautious, citing fatigue from travel as a factor. In Mets vs. White Sox, the Mets are favored. Hauser is unreliable (5.00 ERA in the minors), and the White Sox are 5-21 on the road. Clay Holmes has been strong for the Mets but is nearing workload limits. The duo leans Mets on the run line. Tarek Skubal's dominant performance (13 Ks in a 9-inning shutout) leads into Tigers-Giants. Keiter Montero's poor control (13 BB in 30 IP) makes backing the Giants appealing despite Hayden Birdsong's inexperience. Red Sox-Brewers is another key game. Boston's offense has faltered without Bregman, while Crochet has been elite. Chad Patrick has been solid at home. Josh and Scott prefer a first-five under wager, given offensive struggles. Cubs vs. Rockies is heavily skewed toward the Cubs, with Palmquist's disastrous starts (9 ER in 8 IP, 7 BB) making a run-line play likely. Eric Fedde (Cardinals) is steady, while Charlie Morton (Orioles) has had a volatile season. Despite recent rebound, Morton's early performances were poor, and the line favoring Baltimore is puzzling. In Rangers vs. Blue Jays, both deGrom and Gausman are top-tier arms. Toronto has scored just two runs in three games, and Texas' offense is struggling. Josh and Scott prefer the under, particularly a no-run first inning (Nerf-y) play. Royals vs. Reds also presents a Nerf-y opportunity: Lorenzen is 10-0 to the Nerf-y, and Chris Booback has a 1.45 ERA with 70 Ks in 68 innings. In Rays vs. Twins, Josh praises Tampa's momentum, especially with lineup depth like Chandler Simpson batting seventh. Paddock's 5.19 road ERA and vulnerability in early innings make Tampa appealing. However, Scott warns of fading the Rays later due to a back-loaded road-heavy schedule. Pirates-Diamondbacks features Heaney (8-2 Nerf-y) vs. Ryan Nelson, whose inconsistency and starter-reliever toggling limit trust. Another Nerf-y opportunity is noted. Padres-Marlins showcases Vasquez's steady performances against Weathers, who's shown flashes but is prone to walks and home runs. Yankees vs. Angels sees Yarbrough returning to form, while Kocanowicz has erratic command (20+ walks in 5 starts). Josh recommends betting Yankees and possibly on Kocanowicz's walk prop. The discussion shifts to the mound in Sacramento. Zach Wheeler complained about mound hardness affecting pitch delivery. Scott theorizes high elevation in pitches might stem from poor footing. Josh stresses that pros must adjust, though he criticizes coaches like Minnesota's, who lack firsthand pitching experience and can't offer adjustment strategies. The show ends with a promo code "DAY20" for 20% off at pregame.com and a reminder to enjoy the holiday with plenty of daytime baseball and solid betting opportunities. Learn more about your ad choices. Visit megaphone.fm/adchoices

Former MLB Pitcher Josh Towers and Scott Seidenberg break down the MLB slate of games for Memorial Day This special Memorial Day episode of The Inside Pitch features Scott Seidenberg and former MLB pitcher Josh Towers providing a comprehensive breakdown of the upcoming Monday baseball slate. The podcast focuses on travel dynamics, pitcher performances, betting angles, and how team momentum and logistics influence game outcomes. Central to the discussion is the “Sunday Night Fade”—a strategy of betting against teams that play Sunday night games and must travel before playing again on Monday. Scott cites a 6-1 record with this approach, spotlighting the Dodgers' travel from New York to Cleveland. Josh outlines how travel delays, postgame treatment, and media responsibilities—especially for players like Shohei Otani—can exhaust players, making them vulnerable in early Monday games. Josh and Scott discuss Otani's homer against Kodai Senga, noting it was the first Senga allowed since Opening Day. They analyze the Dodgers-Guardians matchup: Gavin Williams has a strong home record (3-1, 3.40 ERA), but struggles at night (5.09 ERA), while Yamamoto has a 1.00 ERA overall and has not yet pitched in a day game. Despite Yamamoto's strength, Josh is cautious, citing fatigue from travel as a factor. In Mets vs. White Sox, the Mets are favored. Hauser is unreliable (5.00 ERA in the minors), and the White Sox are 5-21 on the road. Clay Holmes has been strong for the Mets but is nearing workload limits. The duo leans Mets on the run line. Tarek Skubal's dominant performance (13 Ks in a 9-inning shutout) leads into Tigers-Giants. Keiter Montero's poor control (13 BB in 30 IP) makes backing the Giants appealing despite Hayden Birdsong's inexperience. Red Sox-Brewers is another key game. Boston's offense has faltered without Bregman, while Crochet has been elite. Chad Patrick has been solid at home. Josh and Scott prefer a first-five under wager, given offensive struggles. Cubs vs. Rockies is heavily skewed toward the Cubs, with Palmquist's disastrous starts (9 ER in 8 IP, 7 BB) making a run-line play likely. Eric Fedde (Cardinals) is steady, while Charlie Morton (Orioles) has had a volatile season. Despite recent rebound, Morton's early performances were poor, and the line favoring Baltimore is puzzling. In Rangers vs. Blue Jays, both deGrom and Gausman are top-tier arms. Toronto has scored just two runs in three games, and Texas' offense is struggling. Josh and Scott prefer the under, particularly a no-run first inning (Nerf-y) play. Royals vs. Reds also presents a Nerf-y opportunity: Lorenzen is 10-0 to the Nerf-y, and Chris Booback has a 1.45 ERA with 70 Ks in 68 innings. In Rays vs. Twins, Josh praises Tampa's momentum, especially with lineup depth like Chandler Simpson batting seventh. Paddock's 5.19 road ERA and vulnerability in early innings make Tampa appealing. However, Scott warns of fading the Rays later due to a back-loaded road-heavy schedule. Pirates-Diamondbacks features Heaney (8-2 Nerf-y) vs. Ryan Nelson, whose inconsistency and starter-reliever toggling limit trust. Another Nerf-y opportunity is noted. Padres-Marlins showcases Vasquez's steady performances against Weathers, who's shown flashes but is prone to walks and home runs. Yankees vs. Angels sees Yarbrough returning to form, while Kocanowicz has erratic command (20+ walks in 5 starts). Josh recommends betting Yankees and possibly on Kocanowicz's walk prop. The discussion shifts to the mound in Sacramento. Zach Wheeler complained about mound hardness affecting pitch delivery. Scott theorizes high elevation in pitches might stem from poor footing. Josh stresses that pros must adjust, though he criticizes coaches like Minnesota's, who lack firsthand pitching experience and can't offer adjustment strategies. The show ends with a promo code "DAY20" for 20% off at pregame.com and a reminder to enjoy the holiday with plenty of daytime baseball and solid betting opportunities. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join Corey Quinn and Travis Weathers—Founder and CEO of Rotate Digital—as he shares how specializing in the moving industry became the catalyst for his agency's explosive growth. From hiring the right sales team to designing a killer commission structure, Travis shares hard-earned lessons on what really drives agency growth, even during economic downturns. If you're an agency founder aiming to scale revenue, retain more clients, and simplify your sales process, this episode is packed with actionable strategies you can put to work today. Episode Highlights: Specialization That Scales — How focusing on one niche fueled Rotate Digital's explosive growth. The Sales Hire That Changed Everything — Why industry knowledge matters less than sales experience. Commission Structures That Actually Work — How to incentivize performance and build a motivated team. Productized for Profit — Why packaging your services can boost revenue and retention. Retargeting Done Right — How Travis uses smart ads to stay top-of-mind and win more clients. Simplicity Sells — Why focusing on business outcomes wins more deals than technical jargon. Sales as Client Experience — How your sales process shapes long-term client satisfaction. Metrics That Matter — The KPIs Travis uses to drive a high-performing sales team. The resources mentioned in this episode are: - Check out Rotate Digital: https://travis@rotatedigital.com - Connect with Travis Weathers on LinkedIn: https://www.linkedin.com/in/travisweathers - Follow Travis on Instagram: https://www.instagram.com/travisweathers - Email Travis: travis@rotatedigital.com - Escape the generalist trap with my best-selling book “Anyone, Not Everyone” and discover how to become the go-to agency in a vertical market https://www.AnyoneNotEveryone.com

Munaf Manji and Griffin Warner talk MLB betting for Tuesday. The guys also give out best bets. The "MLB Tuesday Preview + Best Bets" episode hosted by Munaf Manji with guest Griffin Warner offers a detailed, game-by-game analysis of the MLB slate. Munaf opens by mentioning the excitement surrounding the weekend's games and Juan Soto's return to the Bronx. Griffin begins with the Orioles' implosion, losing despite a 14-3 hit advantage, leading to their manager's firing. He criticizes their underperforming stars like Gunnar Henderson and Adley Rutschman, failed pitching replacements, and Kyle Gibson's poor debut followed by being designated for assignment. Griffin speculates that Brandon Hyde's dismissal, despite being 2023's Manager of the Year, stems from high preseason expectations. Munaf admits he underestimated how poorly the Orioles were performing. They highlight the Cubs vs. Marlins matchup with Jameson Taillon vs. Ryan Weathers. Taillon is untrustworthy as a favorite, while Weathers has promise but is fresh off the IL. Munaf leans on the Cubs' offense, skeptical of Taillon's price. Next, they analyze Reds vs. Pirates. Despite interest in backing Bailey Falter, Griffin is deterred by Pittsburgh's scoring drought—failing to surpass 3 runs in 23 straight games. Nick Martinez has been consistent, while Falter has struggled historically against the Reds. Both lean toward the under 8.5. In the Rangers vs. Yankees game, they discuss Patrick Corbin's surprising stability—holding teams to three or fewer earned runs in all starts this season—and Will Warren's solid form. Though historically bad, Corbin's early-season stats make him a tempting underdog. Munaf supports backing Corbin, noting his past success in Yankee Stadium. They discuss Twins vs. Guardians next, where both support Minnesota. Chris Paddock has rebounded after early struggles, while Gavin Williams hasn't found a reliable swing-and-miss pitch. The Twins' recent 13-game win streak reinforces their pick. The Cardinals vs. Tigers match sees both siding with St. Louis for value. Although Detroit's Skubal is a top Cy Young contender, the Cardinals have been on a hot streak. Eric Fedde, typically inconsistent, has posted strong recent starts. Phillies vs. Rockies analysis is brief—Philadelphia should dominate, especially with Sensatela's 6.39 ERA and 1–7 record. Munaf and Griffin agree on Phillies run line and team total over. In Mets vs. Red Sox, Walker Buehler's IL return raises concerns, and Clay Holmes lacks long-term reliability. Both expect high scoring and back the Mets team total over. Royals vs. Giants features Birdsong's first start for SF. With Kansas City's weak offense and San Francisco's cold bats, both prefer under 8. Angels vs. A's is expected to be a slugfest. Kyle Hendricks and Gunnar Hoglund both provide fade-worthy profiles. They predict double-digit scoring, with Munaf backing the over as his best bet. In Diamondbacks vs. Dodgers, Yamamoto is solid, but Ryan Nelson's fastball-heavy approach is predictable. Dodgers' depth and Arizona's weak bullpen suggest the Dodgers team total over is viable. They close with a quick mention of Braves vs. Nationals, likely featuring Spencer Strider off the IL. Griffin's best bet is Twins -108, trusting Paddock's resurgence and the team's momentum. Munaf selects the Angels-A's over 10 due to suspect pitching and a hitter-friendly park in West Sacramento. They promote a $10 discount using code BUNT10 at pregame.com for season-long picks and wrap up promising continued coverage through the MLB season. Learn more about your ad choices. Visit megaphone.fm/adchoices

Chicago Cubs vs. Miami Marlins MLB Pick Prediction by Tony T. Cubs at Marlins 6:40PM ET—Jameson Taillon gets the start for Chicago. Taillon has nine starts on the season delivering an ERA of 4.53 and WHIP of 1.11. The veteran fans 20.7% with 4.4% walks. Ground balls are 36.7% with 2.36 home runs per nine innings. Ryan Weathers is starting for Miami. Weathers in his 2025 debut allowed one earned run with five strikeouts in five innings at the Cubs.

US markets closed almost unchanged on Monday, despite underlying volatility. The S&P 500 notched its sixth winning session, as investors appeared to look past the recent US credit downgrade. UnitedHealth shares extended their rally after the CEO bought into a beaten-down stock, while Reddit shares slipped amid concerns over a potential threat from Google’s AI developments. Meanwhile, the US dollar weakened following Moody’s downgrade, helping gold prices surge. Closer to home, Australian shares are set to open higher on Tuesday, with attention turning to the RBA and its widely expected interest rate cut. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Aaron Nola has been a disaster (2:30)! ... Sonny Gray also got rocked (10:05). ... Ryan Weathers looked good in his debut (14:00). ... The Dodgers promoted Dalton Rushing but it sounds like he might not play very much (17:55). ... News (24:45): Bryce Miller went on the IL with elbow soreness. ... Rhys Hoskins and Masyn Winn have been on fire (28:50). ... Weathers or Logan Henderson (39:28)? ... Let's have fun with rankings, including Eugenio Suarez, Kyle Stowers, Andy Pages and others (47:58). ... We wrap up with leftovers, bullpen updates and streamers (1:00:30). Fantasy Baseball Today is available for free on the Audacy app as well as Apple Podcasts, Spotify and wherever else you listen to podcasts.  Subscribe to our YouTube channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/FantasyBaseballToday⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Download and Follow Fantasy Baseball Today on Spotify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://sptfy.com/QiKv⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Get awesome Fantasy Baseball Today merch here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://bit.ly/3y8dUqi⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow FBT on TikTok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@fbtpod?_t=8WyMkPdKOJ1&_r=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow our FBT team on Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@FBTPod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@CPTowers⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@CBSScottWhite⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@Roto_Frank⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Join our Facebook group at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/groups/fantasybaseballtoday⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Sign up for the FBT Newsletter at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.cbssports.com/newsletters/fantasy-baseball-today/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ For more fantasy baseball coverage from CBS Sports, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.cbssports.com/fantasy/baseball/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ To hear more from the CBS Sports Podcast Network, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.cbssports.com/podcasts/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ You can listen to Fantasy Baseball Today on your smart speakers! Simply say "Alexa, play the latest episode of the Fantasy Baseball Today podcast" or "Hey Google, play the latest episode of the Fantasy Baseball Today podcast." To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Miami Marlins vs. Chicago Cubs MLB Pick Prediction by Tony T. Marlins at Cubs 7:40PM ET—Ryan Weathers will start for Miami. Weathers makes his debut after a forearm strain in spring training. He had sixteen starts last year with an ERA of 3.63 with WHIP of 1.18. The left hander struck out 21.8% with 6.5% walks. Ground balls served at 46.6% with 1.14 home runs per nine innings.

Lexington Police Chief Lawrence Weathers joins Jack in Studio for his monthly visit to talk about a current missing persons case and and expected uptick in crime over the summer months. See omnystudio.com/listener for privacy information.

  The Ruckus Report Quick take: This experimental episode explores emerging educational trends with Mitch Weathers, diving into AI's impact on teaching, the evolution of education's purpose, and whether teaching remains a recommendable profession. Meet Your Fellow Ruckus Maker Mitch became a gifted teacher because he was a mediocre student. Despite taking seven years to graduate college, he navigated the classroom with discomfort. This unique perspective fueled Mitch's teaching approach. Recognizing the importance of laying a foundation for learning, he created Organized Binder. This research-backed strategy empowers teachers to impart executive functioning skills efficiently, preserving valuable instructional time. By establishing a predictable routine, Organized Binder fosters safer learning spaces, shaping Mitch's journey from a struggling student to an innovative educator. Breaking Down the Old Rules

Educator, speaker and author Mitch Weathers joins the pod to discuss his method for maximizing student success with the Organized Binder method. Students, teachers and parents have noticed the cognitive load placed on our kids year after year, but are baffled as to the process in which to build these skills and improve executive functioning and success in school, and Mitch Weathers has come up with a process to fix those issues.  — We want to hear from you! Shoot over an email and say hi: podthebalancingact@gmail.com Don't forget to subscribe! Leave us a comment!    Follow  Facebook - podbalact JoeandJamie Instagram - @podthebalancingact TikTok - @thebalancingactpodcast Youtube Channel - The Balancing Act - YouTube Part of the Human Content Podcast Network Learn more about your ad choices. Visit megaphone.fm/adchoices

Derek Shulman and John Weathers never looked back, and maybe that's why Gentle Giant's music still stares you The post Gentle Giant's Derek Shulman and John Weathers appeared first on The Strange Brew .

April 2025 Dante's Old SouthBuffalo Nichols: Texas based, Milwaukee raised, Buffalo Nichols is known as an acoustic blues guitarist and singer but that isn't the whole story. Two albums into his career, Nichols has proven himself to be an innovative songwriter with lyrics address both personal and political themes with biting insight. His influences range from his time playing in Baptist churches to his many years playing guitar in West African music bands. His experimental and hip-hop influences are displayed as well on his 2023 album, The Fatalist'. Nichols' self-titled  debut, released in October 2021, ascended him to the national stage, earning praise and support from NPR Music (‘Tiny Desk (Home) Concert;' All Songs Considered ‘Best of October') to Rolling Stone ('The Fight to Reclaim the Blues' feature; ‘Song You Need To Know'), Bandcamp Daily (‘October Shortlist') to Guitar World, Texas Monthly to Uncut (UK), among many others. www.buffalo-nichols.com/www.instagram.com/buffalonicholsmusic/Odessa Blaine: General oddment and possible cryptid, Odessa haunts the mountains and coffee shops of North Georgia. Her novels and short stories incorporate elements drawn from her Appalachia roots. Odessa has honed her skills as a performance storyteller and loves sharing stories with live audiences. When she's not slinking through the woods or over-caffeinating, Odessa can be found encouraging the creative passions of others by serving multiple writer focused nonprofits based in the Southeast and providing marketing and project management to small businesses.  substack.com/@odessablainebsky.app/profile/odessablaine.bsky.socialJenny Bates enjoys seven poetry books, published in numerous NC and international journals. Jenny was a judge for the Poetry in Plain Sight contest through the NC Poetry Society, 2024. Her book of poems, ESSENTIAL has been nominated for the Pushcart Prize 2024. Her newest collection, From Soil and Soul is available. Jenny's books are also available at Malaprops Bookstore in Asheville, Bookmarks, the Book Ferret and The Book House in Winston-Salem, Scuppernongs in Greensboro, NC.redhawkpublications.com/Poetry-c120141004www.malaprops.comthebookhousews.comwww.bookferret.comCynthia Atkins: (She, Her), is a prizewinning poet originally from Chicago, IL and the author of Psyche's Weathers, In the Event of Full Disclosure, and Still-Life with God, and Duets from Harbor Editions.  Her work has appeared in Alaska Quarterly Review, BOMB, Diode, Cimarron Review, Los Angeles Review North American Review, Permafrost, Plume, and Verse Daily. Atkins has earned fellowships and prizes from Bread Loaf Writers' Conference. SWWIM Residency, Virginia Center for the Creative Arts, and Writers at Work.  Atkins lives on the Maury River of Rockbridge County, Virginia, with artist Phillip Welch and their family. More info at: www.cynthiaatkins.comOur Sponsors:Lucid House Press: www.lucidhousepublishing.comWhispers of the Flight: www.amazon.com/Whispers-Flight-Voyage-Cosmic-Unity-ebook/dp/B0DB3TLY43The Crown: www.thecrownbrasstown.comBright Hill Press: www.brighthillpress.orgInvisible Strings 113 Poets Respond to the Songs of Taylor Swift: www.penguinrandomhouse.com/books/777808/invisible-strings-by-edited-by-kristie-frederick-daughertyWe Deeply Appreciate:UCLA Extension Writing Program: www.uclaextension.eduMercer University Press: www.mupress.orgThe Red Phone Booth: www.redphonebooth.comNPR: https: www.npr.orgWUTC: www.wutc.orgAlain Johannes for the original score in this show: www.alainjohannes.comThe host, Clifford Brooks', The Draw of Broken Eyes & Whirling Metaphysics, Athena Departs, and Old Gods are available everywhere books are sold. Find them all here: www.cliffbrooks.com/how-to-orderCheck out his Teachable courses, The Working Writer and Adulting with Autism, here: brooks-sessions.teachable.com

“This is not good for China's economy, but they have staying power, and I don't see them backing down.” While the pandemic years were tough on China's economy, the country has recently recovered financially, recording a 5 percent growth rate last year. China is also becoming increasingly less dependent on exports to the United States and is diversifying investments in Southeast Asia, putting it in a good position to weather the storm of U.S. tariffs. Scott Kennedy, CSIS senior adviser and Trustee Chair in Chinese Business and Economics, joins the podcast to discuss the latest in the U.S.-China trade war, including China's technological capabilities, new export controls, and the possibility of future decoupling.

In this special episode from The Truth of the Matter from CSIS, host Andrew Schwartz speaks with Scott Kennedy, CSIS senior adviser and Trustee Chair in Chinese Business and Economics, to discuss the latest in the U.S.-China trade war, including China's technological capabilities, new export controls, and the possibility of future decoupling. Original interview published on April 17, 2025.

I Wish / SKEE-LO 4:11 Rétro Laser / Le Jouage & James Delleck 3:25 Vomitspit Daydream / Tanda 3:17 Fargo (Feat. Wais P) / Termanology & Bronz... 2:35 My Last Breath (Feat. Stallone & Weathers)... 3:15 TV Extravaganza (prod. by Leeroy Destroy) /... 2:40 Prussian Blue / White Shadow & Son Of Sat... 3:42 Toodeloo / Homeboy Sandman & Yeyts 1:56 When The Metal Hits / Kingdom Kome & On... 3:31 Ballin At Last (Feat. Homeboy Sandman) / Sl... 4:11 Rabbit Hole (Feat. MysDiggi) / Ramson Bad... 3:37 Remain Strong feat. Masta Ace & Wordswor... 3:19 Mysterious Things / Brother Ali & Ant 3:54 Men From Boys feat. Hell Razah / Solomon... 2:17 For All Of Ya (Feat. Fashawn) / Al Rock 2:43 Back To The Essence / J-Live 3:35 On the Corner (feat. Born Unique, Goretex... 3:49

In this episode, Kyleigh describes her wellness journey from suffering a spinal cord injury, leaving the Mormon culture, getting married, having a child and coming out as a lesbian. She now helps the LGBTQ + community through their trauma/abandonment patterns into healthy-pattern relationships. We talk about the power of owning your own choices and how emotions don't want to stay in your body. She helps others recognize that if an unhealthy pattern started within them, the solution also resides within. https://queerlyattached.net/attachment-quizHome - Queerly Attached(203) Queerly Attached - YouTubeQueer Attachment Coach—Kyleigh Weathers (@queerlyattached) • Instagram photos and videosTikTok - Make Your Day#alittlelessfearpodcast #drlinomartinez #attachment #attachmentstyles #queerattachmentstyles #queerattachment #queer #lgbtqplus #lgbtq #mentalhealth #wellness #motivationThis is Dr. Lino Martinez the host for A Little Less Fear Podcast. For more information, please use the information below. Thanks so much for your support!Author | A Little Less FearA Little LESS FEAR Podcast (@alittlelessfearpodcast) • Instagram photos and videosLino Marinez (@alittlelessfear) TikTok | Watch Lino Marinez's Newest TikTok Videos(4) A Little Less Fear Podcast - YouTube

Check out Community Radio on TuneIn, Live 365, and Audacy for more information!

LaJuana Weathers, Aunty of Afriware Books owner Nzingha Nommo reflects on her father Frederick Douglass Gayden. He owned four dry cleaning businesses in the 1940s.

Ryan Weathers has a forearm injury and will miss the first 4-6 weeks of the regular season. We have updates on Gunnar Henderson and Felix Bautista. Shane Smith will be on the White Sox Opening Day roster.

Stephen Strom and Jack McMullen sit down with Ryan Weathers to chat about his Spring Training, expectations, weight loss and his journey as he enters year five of his big league career. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Lexington Police Chief Lawrence Weathers joins Jack in studio to talk about the recent rise in fatal shootings around town and to take your calls and questions on #LEX. See omnystudio.com/listener for privacy information.

Gideon tests the mood in Kiev three years after the Russian invasion as the Trump presidency upends previous tenets of international politics. He talks to Ukrainian MP Lesia Vasylenko and Oleksandr Khomiak, director of Drone Space Labs, a defence start-up. Clip: European CommissionFree links to read more on this topic:Ukraine agrees minerals deal with USUS drives Ukraine war measure through UN with Russian backingVolodymyr Zelenskyy's toughest battle beginsNow is the time for Europe really to step up on UkraineSubscribe to The Rachman Review wherever you get your podcasts - please listen, rate and subscribe.Presented by Gideon Rachman. Produced by Fiona Symon. Sound design is by Breen Turner.Follow Gideon on X @gideonrachmanRead a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

The secret to student success might not be what you think. Our guest reveals why executive functioning skills—the ability to organize, manage time, set goals, and complete tasks—form the foundation for all learning yet are rarely taught explicitly in schools. Through his personal story of classroom struggles, he shares how he developed an innovative approach to embedding these skills naturally into daily routines. Tune in to learn why his book on executive functioning became an instant bestseller and how his "Organized Binder" approach is transforming classrooms across the country.IN THIS EPISODE, WE DISCUSS:Why some students naturally "get" school while others struggle despite their intelligence and effort The hidden skills that are rarely taught but essential for academic success A practical approach to embedding executive functioning skills into classroom routines without adding to a teacher's workloadRESOURCES AND LINKS MENTIONED IN THIS EPISODE:Connect with Mitch:organizedbinder.com https://www.instagram.com/organizedbinder/https://x.com/organizedbinderhttps://www.facebook.com/organizedbinderhttps://www.linkedin.com/in/mitchweathers/Email: mitch@organizedbinder.comBook: Executive Functions for Every Classroom, Grades 3-12: Creating Safe and Predictable Learning EnvironmentsThe 90-Day Accelerator is opening soon, and waitlist members get two live coaching calls plus exclusive leadership courses ($750 value). Claim your spot → https://90-day-waitlist.carrd.co/?rootabl=tanyasheckley Learn more about the Rebel Project Literacy Curriculum, a fully integrated literacy and project based learning curriculum, at  projectup.us or inkwire.co/rplc Get your copy of Rebel Educator: Create Classrooms Where Impact and Imagination MeetLearn more about Rebel Educator, explore our professional development opportunities for educators and students, and check out our project library.Visit us at UP Academy to learn more about our personalized and inclusive learning environment.Connect with Tanya and UP Academy on LinkedIn, Facebook, and Instagram and learn more about her journey here.GUEST BIO:Mitch became a gifted teacher because he was a mediocre student. He rarely felt comfortable in the classroom. In fact, it took him 7 years for him to graduate from college.Choosing to become a teacher, Mitch was fortunate enough to experience school as if it was happening all around him. He was unsure how to jump into his learning with confidence. There is a loneliness to experiencing your education as a passive object as opposed to an active subject.From the moment he entered the classroom, Mitch relied on his personal experiences as a learner. He recognized that what we teach, the content or curriculum is secondary. We must first lay the foundation for learning before we can get to teach. In fact, unless students develop a solid foundation for learning it does not matter how great your teachers deliver content, or how emergent the technology, or even how engaging a lesson might be.Mitch designed Organized Binder to empower teachers with a simple but research-backed strategy to teach students executive functioning skills while protecting the time needed for content instruction. The secret is found in establishing a predictable learning routine that serves to foster safer learning spaces. When students get practice with executive functions by virtue we set them up for success.Enjoying the show? Leave us a rating and review and help more people find us!bit.ly/RebelEducatorApplePodcastsWe'd love it if you could take a few minutes to fill out this survey to let us know how we can bring you the best possible content: forms.gle/JcKHf9DHTZnYUmQr6 Interested in being on the Rebel Educator podcast? Fill out this form and we'll reach out to you if we think you'd be a great fit for an upcoming episode. https://forms.gle/CZJXLQDdevPh22ZN7Want to learn more about opening your own UP Academy? Check out the Rebel Educator Accelerator:www.rebeleducator.com/courses/the-acceleratorMORE ABOUT THE REBEL EDUCATOR PODCAST:In each episode of the Rebel Educator podcast, I deconstruct world-class educators, students, and thought leaders in education to extract the tactics, tools, and routines that you can use as teachers and parents. Join me as we discuss how to shift the classroom, the learning environment, the mindset, and the pedagogy, to resist tradition, reignite wonder, and re-imagine the future of education.This podcast is dedicated to all of the educators who work thankless hours to make our next generation the best it can be.  It was designed to begin conversations on how we can redesign education for the future of work and the success of our students.  It is meant for teachers, students, administrators, homeschoolers and anyone who interacts with and teaches youth.Ever wish you had a blueprint for transforming your school without drowning in administrative tasks?The 90-Day Accelerator is opening soon, and waitlist members get two live coaching calls plus exclusive leadership courses ($750 value). Claim your spot → https://90-day-waitlist.carrd.co/?rootabl=tanyasheckley We're thrilled to be sponsored by IXL. IXL's comprehensive teaching and learning platform for math, language arts, science, and social studies is accelerating achievement in 95 of the top 100 U.S. school districts. Loved by teachers and backed by independent research from Johns Hopkins University, IXL can help you do the following and more:Simplify and streamline technologySave teachers' timeReliably meet Tier 1 standardsImprove student performance on state assessments

This week, Sam has driven the Genesis GV80 Coupe while Nicole had the 2025 Chevrolet Traverse. Nicole, Robbie and Sam all had a chance to drive the updated the 2025 Hyundai Ioniq 5 including the off-roady XRT model. In the news this week, the General Services Administration has decided that federal government facilities don’t need… Read More »All The Weathers

This week a light-hearted (and therefore much-needed!) tribute to the marvelous Felicia Weathers, who, in the midst of her burgeoning operatic career in the late 1960s, made two LPs of Schlagermusik, 1968's Liebe Love L'amour (which also sports the best record cover in the history of the LP!) and, the following year, Wunderbar ist die Welt. Both of these were arranged and conducted by one Harold M. Kirschstein, referred to in the liner notes as an important conductor and arranger. Imagine my surprise when, upon doing a little research, I discovered that this person was better known in his native United States as Henri René, whom I knew from his work with Eartha Kitt in the early days of her recording career. His arrangements are, of course, predictably delightful. Amid all her other successes, Felicia Weathers (like Maria Ewing a generation later) found her greatest fame performing the title role of Richard Strauss's Salome. This role may have put strain on her voice and shortened her career, but in the late 1960s her voice, as captured on these recordings, was a beguilingly beautiful instrument. She also displays a fine interpretive approach, keen linguistic sense, and vital communicative powers to these songs, which feature some of my favorite melodies ever, including those written by Georges Auric, Jimmy Webb, Harold Arlen, Henry Mancini, Jean-Paul Egide Martini, Oscar Straus, and Friedrich Hollaender. I supplement these delicious selections with two Rodgers and Hammerstein medleys from Weathers' 1969 album of songs from musicals, Hello, Young Lovers, which also features duets with the superb African American baritone William Ray, who was also based in Europe during those years. Enjoy this delicious, if brief, escape from reality! Countermelody is a podcast devoted to the glory and the power of the human voice raised in song. Singer and vocal aficionado Daniel Gundlach explores great singers of the past and present focusing in particular on those who are less well-remembered today than they should be. Daniel's lifetime in music as a professional countertenor, pianist, vocal coach, voice teacher, and journalist yields an exciting array of anecdotes, impressions, and “inside stories.” At Countermelody's core is the celebration of great singers of all stripes, their instruments, and the connection they make to the words they sing. By clicking on the following link (https://linktr.ee/CountermelodyPodcast) you can find the dedicated Countermelody website which contains additional content including artist photos and episode setlists. The link will also take you to Countermelody's Patreon page, where you can pledge your monthly or yearly support at whatever level you can afford.

Lexington Police Chief Lawrence Weathers joins Jack to talk about the continuing effort to recruit more officers here in the city and gives his thoughts on if ICE agents should be allowed to raid schools on #LEX. See omnystudio.com/listener for privacy information.

On this episode, Chris and Koi shoot the shit about a bunch of stuff! Is a relationship even in peoples agenda today? How much harder do you think would it be to date if you were a celeb or a ball player  The boys vs a gf  Do you think relationships differ in other states because of the weather  Weathers getting nice….. Don't let your kid order at a fast food restaurant  People that's been married 2 or 3 times 

In Episode 87, Cindy chats with Mitch Weathers, a veteran teacher and Founder and CEO of Organized Binder. Mitch discusses what exactly is meant by executive functioning, his own learning struggles as a student, and his many projects aimed at improving students' executive functioning skills including his recently released book, Executive Functions for Every Classroom: Creating Safe and Equitable Learning Environments. 

Pete Hegseth weathered all sorts of Democrat Senators' attacks from accusations without evidence from anonymous sources to ability to push pencils to leadership ability as they resorted to character assassination during his Defense Secretary Confirmation Hearings on Tuesday. He fired back at silly questions from the likes of Sens. Hirono, Warren, Blumenthal, et al while showing the country he has the thick skin and ability to lead and overhaul how things get done within the DoD. Dr. Jerome Corsi breaks down what happened on The Truth Central. Also:A new tape (played on InfoWars) exposes new information raising suspicions of LBJ's involvement with John F. Kennedy's assassinationThe continued failures of the EV (lack of) movementA retirement crisis is looming and it could be worse than you thinkIf you like what we are doing, please support our Sponsors:Get RX Meds Now: https://www.getrxmedsnow.comMyVitalC https://www.thetruthcentral.com/myvitalc-ess60-in-organic-olive-oil/Swiss America: https://www.swissamerica.com/offer/CorsiRMP.phpGet Dr. Corsi's new book, The Assassination of President John F. Kennedy: The Final Analysis: Forensic Analysis of the JFK Autopsy X-Rays Proves Two Headshots from the Right Front and One from the Rear, here: https://www.amazon.com/Assassination-President-John-Kennedy-Headshots/dp/B0CXLN1PX1/ref=sr_1_1?crid=20W8UDU55IGJJ&dib=eyJ2IjoiMSJ9.ymVX8y9V--_ztRoswluApKEN-WlqxoqrowcQP34CE3HdXRudvQJnTLmYKMMfv0gMYwaTTk_Ne3ssid8YroEAFg.e8i1TLonh9QRzDTIJSmDqJHrmMTVKBhCL7iTARroSzQ&dib_tag=se&keywords=jerome+r.+corsi+%2B+jfk&qid=1710126183&sprefix=%2Caps%2C275&sr=8-1Join Dr. Jerome Corsi on Substack: https://jeromecorsiphd.substack.com/Visit The Truth Central website: https://www.thetruthcentral.comGet your FREE copy of Dr. Corsi's new book with Swiss America CEO Dean Heskin, How the Coming Global Crash Will Create a Historic Gold Rush by calling: 800-519-6268Follow Dr. Jerome Corsi on X: @corsijerome1Become a supporter of this podcast: https://www.spreaker.com/podcast/the-truth-central-with-dr-jerome-corsi--5810661/support.

Jack has assembled his A-Team and has all the answers from all of the most important people around town concerning the severe winter weather as he talks with Lexington Police Chief Lawrence Weathers. See omnystudio.com/listener for privacy information.

Blood-based biomarkers for dementia diagnosis are emerging and rapidly evolving. These fluid biomarkers should be used when the results will impact management decisions, including patient and family counseling, symptomatic therapies, and disease-modifying therapies. In this episode, Allison Weathers, MD, FAAN, speaks with Joseph F. Quinn, MD, FAAN, an author of the article “Fluid Biomarkers in Dementia Diagnosis,” in the Continuum® December 2024 Dementia issue. Dr. Weathers is a Continuum® Audio interviewer and associate chief medical information officer at the Cleveland Clinic in Cleveland, Ohio. Dr. Quinn is a professor in the Department of Neurology at Oregon Health & Science University in Portland, Oregon. Additional Resources Read the article: Fluid Biomarkers in Dementia Diagnosis Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Transcript Full interview transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Weathers: This is Dr Allison Weathers. Today, I'm interviewing Dr Joseph Quinn, author along with Dr Nora Gray, of Fluid Biomarkers in Dementia Diagnosis from the December 2024 Continuum issue on dementia. Welcome to the podcast and please introduce yourself to our audience. Dr Quinn: Sure. I'm Joe Quinn. I'm a neurologist at the medical school in Oregon, Oregon Health Science University, and I work in neurodegenerative disease, Alzheimer's disease, and Parkinson's disease.  Dr Weathers: Certainly some really weighty topics. But again, as I said, today we want to focus on a really fascinating one, the concept of fluid biomarkers in dementia diagnosis. And we'll perhaps get into monitoring of treatment as well. So, this search for reliable biomarkers in the diagnosis of dementia, certainly not a new topic, but you and your co-author Dr Nora Gray did a really fantastic job in the article right from the get-go, laying out the urgency around this now that there are FDA of treatments that depend on pathologic diagnosis. And it feels like they're more and more announced by the day. Even as I was preparing for this interview a few days ago, the FDA approval for donanemab was announced, with the news making every major media outlet. Well, there are several really critical points made by you both in the article. What do you feel is the most important clinical message of your article? What do you want our listeners to walk away with as their one key takeaway?  Dr Quinn: I think we still have the best evidence for CSF biomarkers, cerebrospinal fluid biomarkers, really making a diagnosis with some confidence. PET scans are available for visualizing amyloid and Tau now, but they're so expensive and they're not covered. So, the spinal tap information is what most of us around here really rely on when we want to be sure about what's going on. The blood tests are very promising, very exciting, but as you probably know, there's a lot of different opinions about this out there. Some people are sure that it's a done deal and that we now have a blood test for Alzheimer's disease. After I sent the article off, I opened up my issue of Neurology and there was an editorial saying these blood tests will never work. So, there's different ends of the spectrum on this and we tried to strike a balance with that. So they're very promising. I think before the article is due for revision, things are going to be different. But right now, spinal fluid is probably where we have the most confidence. Dr Weathers: I think that's a really solid takeaway to start our discussion with. And then, I think you both did really strike that very delicate balance in what is right now an area where, as I said, you know, things still are changing by the day. I know for our listeners who do subscribe, and I hope that most of them do, Table 9.1, clinically useful CSF biomarkers for the differential diagnosis of dementia, is one that I personally think I will frequently return to. You and Doctor Gray did just a wonderful job organizing these very complex concepts into an easy read and really powerful tool, especially for use at the bedside. Along the lines of knowing which biomarker to use, how frequently routine care are you ordering these tests on your patients? And do you anticipate this changing the media future? Is this another one of those things that by next week, we'll have a different kind of answer in how we use these tests? Dr Quinn: Yeah, as you said in your preliminary comments, the whole picture has been changed by the approval of these antibody therapies for Alzheimer's disease, lecanumab and just last week, donanemab. Prior to the approval of those two medications, I didn't use spinal fluid tests routinely, but I relied on them when I really needed to make a diagnosis with certainty of something really important hung in the balance. If we were trying to rule out some other treatable, more treatable problem. You know, for example, if it was a question of whether somebody primarily had a psychiatric problem or a neurodegenerative disease, this is something that would really allow me to objectify things. And- but that was a minority of people that I would see for dementia evaluation. You know, now that the two therapies are approved, I'm not actively engaged in administering those therapies very frequently but I can see already that the, the patients that I am discussing this with that spinal fluid is where we're probably going to rely for making a diagnosis of the amyloid burden in the in the living patient until PET scans are approved. If amyloid PET scans are- not approved, but covered by insurance, then those will probably replace the spinal fluid. So those tests in that table, A beta 42, tau, p-tau, one of them that's relatively new is this test for aggregated alpha-synuclein. Those I order with some frequency when I'm in those circumstances.  Dr Weathers: That's really helpful for our listeners to hear from an expert such as yourself and to think about as they encounter similar patients. Whenever discussing complex topics such as this one, I'm always curious about, what is the most common misconception or pitfall regarding the use of biomarkers for the diagnosis of Alzheimer's and other dementia that you encounter?  Dr Quinn: With respect to the blood biomarkers, you know, we were saying a moment ago that there's a lot of evidence available, but the jury is still out to some degree as to how reliable they are. And I think an important message with respect to those blood biomarkers is that they really are confounded by comorbidities. Remember, we're dealing with an elderly population, so comorbidities like hypertension and renal insufficiency and those kinds of things are relatively common and they can really throw off the blood biomarkers in a more dramatic way than cerebrospinal fluid biomarkers. The other fact, and I can't remember how well we cited this in the article, was that the blood biomarkers don't perform as well in underrepresented minorities. And you know, all of us are appropriately paying more attention to that problem in our practice of medicine. And for these blood biomarkers, that's a real issue. And whether the inferior performance in underrepresented groups is due to more comorbidity or just due to genetic differences is unclear at this time. So those are really important cautions. We mentioned the renal insufficiency and, I think, some of the other comorbidities, but it's a reason to really be careful with the blood biomarkers.  Dr Weathers: I think a really important point, especially again, kind of going back to what we were talking about at the beginning of our discussion, there's so much excitement around them. There's so much potential. People think we finally have that kind of silver bullet of diagnosis. So, I think really something to keep in mind.  What about in the use of their- in monitoring the efficacy of treatments?  Dr Quinn: So that's I think a little earlier in its history in terms of what biomarkers would be useful for monitoring. But the donanemab trial really relied on blood biomarkers as outcome measures and really showed some interesting phenomena. One of them was that plasma neurofilament light, which is all the rage now and all over neurology, people are measuring plasma neurofilament light. It's a nonspecific marker of neuronal damage that makes it out into the serum. So, you can measure it in serum and detect CNS damage in the serum. And intuitively, you would think that would be a good measure of efficacy, but in terms of detecting a treatment effect with donanemab, it didn't perform very well. Conversely, GFAP, which is a marker of astrocyte activation, which I would not have predicted was going to be a sensitive marker for treatment efficacy, performed well in at least the donanemab trial. So, I think it's early in the history of using these markers as outcome measures in clinical trials. And I think we're going to continue to learn as each therapy comes along and as these things come to pass.  Dr Weathers: Don't make any assumptions yet? Would that be a good way to sum that up?  Dr Quinn: I think that's, yes. I think that's very fair that that we have to be careful about these things.  Dr Weathers: OK. So, in summary, I think, does it sound like it's fair to say that the pitfall might be to say it's too early to make any assumptions or any conclusions quite yet? Dr Quinn: That's right. And, and I think, you know, we're going to need to monitor these therapies. I think all of us in neurology have become very accustomed to how you do that in multiple sclerosis, right? We've got MRI scans to be used to monitor therapy, maybe NFL is going to be an appropriate assay there as well. But, you know, there we've all had the experience of a chronic disease and seeing how well your therapy is doing, changing therapy if it fails. So, we're absolutely going to need those things in in Alzheimer's disease and other neurodegenerative diseases, but it's a little early for us to be sure exactly what the right measures are to make those important decisions. Dr Weathers: And a lot more work to be done for sure. As I mentioned, this is a topic of such great interest and I know, you know, certainly most of our listeners are neurologists or people in our world, medical students and trainees. I know I have one regular nonneurologist listener, my father. He really gets a kick out of listening to my interviews. Even though he is a retired sales manager from IBM and most of the time the topics of discussion are pretty different from his usual favorite podcasts. But this one he will be particularly interested in and I'm sure I will get a list of questions about, particularly because my grandfather unfortunately had Alzheimer's disease. So, I'm sure one of his questions will be about the use of these biomarkers in asymptomatic patients. How do you counsel family members of patients when they inquire about the use of biomarkers for that youth case? What is their utility in presymptomatic testing? Dr Quinn: We know from studies like the Alzheimer's disease neuroimaging initiative and other biomarker studies that some of these markers will be sensitive to pathology. Even in asymptomatic people, that pathology appears long before people develop symptoms. Despite that, I don't recommend that asymptomatic people get any of the testing right now because we do not have evidence that early intervention at the completely asymptomatic stage is valuable. And those clinical trials are underway. There are trials underway right now for people who don't even meet the memory deficit required to have a diagnosis of mild cognitive impairment, people who are entirely cognitively intact, but who on one biomarker study or another have evidence of pathology burden. And the interventions are being started early. And in a few years, we'll know the answer to that. Right now, for somebody to find out that they have pathology without any ability to act on it, I think is not valuable. So, I discourage people from pursuing that.  Dr Weathers: And that is really important guidance. Thank you. I know you have, as you mentioned, a beginning in a really diverse neurologic background with expertise, as you said, not only in dementia, but also in Parkinson's disease. And you didn't even mention this, but I know expertise in stroke as well, but your research has been primarily in Alzheimer's. What drew you to dementia and to this specific the aspect of it? How did you become an expert in biomarkers?  Dr Quinn: Well, I'll start with the dementia part. So, you know, I was always just interested intuitively in trying to understand how, you know, the brain mediates the mind. So as an undergraduate, I got started working in a lab that was working on the cholinergic system in the brain, which was still being sorted out at that time. It is important in Alzheimer's disease, but it was really where the focus was. And that's what got me interested in Alzheimer's disease, which incidentally is what got Alzheimer interested in Alzheimer's disease. You know, he was very interested in trying to find the biological footprints of all these different neurological and psychiatric diseases. And he usually came up empty-handed until he came across the patient with Alzheimer's disease where there were actual footprints in the brain that he thought was pointing towards what was going on. And we're still wondering about that a hundred years later, I guess that's how I got interested in dementia and Alzheimer's disease. I think I have always spent part of my time as a clinician. I think that's what got me interested in biomarkers, that this problem has always been there that, you know, we've got quite, you know, research criteria for making diagnosis and all that sort of thing. But we've really needed some biological evidence to help us firm this up even before the availability of the therapies. And that's what got me interested in- I'm making another point. I thought that computer research biomarkers are going to help point me towards the causes of the disease, and unfortunately that part hasn't entirely panned out. We've got some research in that area on micro-RNA biomarkers that maybe will bear some fruit down the road, but that's been a tougher, tougher nut to crack. Dr Weathers: But it's so incredibly important work. Well, this has been wonderful. I really enjoyed our conversation, and I always like to end on a hopeful note. What developments in the biomarker space are coming on the horizon are you most excited about? Dr Quinn: I'm hoping that these biomarkers that allow us to evaluate disease efficacy, blood biomarkers that don't require extraspinal taps and that sort of thing. I hope that all comes to pass. And I do think that there is a lot of research underway looking at biomarkers in a novel way that I think could help point us to new targets for therapy, things that you and I haven't even thought of yet. Those are the two things. I guess you asked me for one, I gave you two.  Dr Weathers: Oh I think very fair. I agree. Both of those would certainly be wonderful and, and I'm excited as well. Well, thank you, Dr Quinn, for taking the time to speak with me this evening.  Dr Quinn: A pleasure. Thank you for having me. Thank you for inviting me to do the piece. It was really a great experience.   Dr Weathers: Again, today I've been interviewing Dr Joseph Quinn, who's written with Doctor Nora Gray on fluid biomarkers and dementia diagnosis. This article appears in the December 2024 Continuum issue on Dementia. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

durée : 00:02:35 - La chronique de Frederick Sigrist - par : Frédérick Sigrist - On apprend la disparition de Carl Weathers, l'Apollo Creed des films "Rocky", le rôle de Dillon dans "Predator", un charisme de dingue, des muscles dans lesquels on peut faire vivre trois Pierre Niney, et une filmographie qui a fait le bonheur des gros geeks barbus à casquettes.

What if the key to thriving as an educator lies in the same skills we often teach our students? In this inspiring episode of Aspire to Lead, Mitch Weathers, author and creator of Organized Binder, takes us on a deep dive into the world of executive functioning—not just for students, but for educators themselves. Mitch unpacks how a foundation of predictable routines, intentional practice, and emotional regulation can transform your approach to teaching and leadership. Together, we explore how modeling executive functioning skills in the classroom fosters a culture of success, and why practicing these strategies as educators is vital for staying grounded and effective. But this isn't just about structure—it's about embracing tools that help you navigate the chaos of education with confidence and purpose. Tune in to discover practical ways to elevate your daily routines, improve emotional resilience, and truly lead by example. Whether you're an educator or leader, this conversation with Mitch Weathers will leave you feeling inspired and equipped to take your professional growth to the next level! About Mitch Weathers: Mitch became a gifted teacher because he was a mediocre student.  Mitch rarely felt comfortable in the classroom. In fact, it took him 7 years for him to graduate from college.  Choosing to become a teacher, Mitch was fortunate enough to experience school as if it was happening all around him. He was unsure how to jump into his learning with confidence. There is a loneliness to experiencing your education as a passive object as opposed to an active subject.  From the moment he entered the classroom Mitch relied on his personal experiences as a learner. He recognized that what we teach, the content or curriculum, is secondary. We must first lay the foundation for learning before we can get to teaching.  Mitch designed Organized Binder to empower teachers with a simple but research-backed strategy to teach students executive functioning skills while protecting the time needed for content instruction. The secret is found in establishing a predictable learning routine that serves to foster safer learning spaces. When students get practice with executive functions by virtue we set them up for success.  Follow Mitch Weathers: Website: www.organizedbinder.com  Twitter: https://twitter.com/organizedbinder  Instagram: https://www.instagram.com/organizedbinder/  Facebook: https://www.facebook.com/organizedbinder  Linkedin: https://www.linkedin.com/in/mitchweathers/  Vimeo OB showcase:

On this week's American Prestige news roundup: 2024 is officially the hottest year on record (0:57), particularly because the Arctic is no longer a carbon sink, but rather a net carbon emitter (2:40); regarding the situation in Syria, an update on the political transition (5:16), renewed fighting between the SDF and Turkish proxies (10:56), and Israel makes a land grab for an extended "buffer zone" (15:01); in Israel-Palestine, Hamas makes a major ceasefire concession (18:22); rebels in Myanmar seize the Bangladesh border (21:29) while other factions call for a ceasefire (22:51); President Yoon of South Korea survives his first impeachment vote and chaos ensues (24:30); Ethiopia and Somalia strike a deal to settle their recent tensions (30:14); in Russia-Ukraine, Trump's demand for a ceasefire panics Zelenskyy (33:22); Romania's constitutional court annuls the first round of its presidential election (37:14); an armed group commits a massacre in Haiti (40:25); and the Biden administration is building migrant detention facilities (42:00).Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Lewy body dementia is a common cause of cognitive impairment in older adults but is often subject to significant delays in diagnosis and treatment, increasing the burden on patients and family caregivers. Understanding key features of the disease and use of biomarkers will improve recognition. In this episode, Allison Weathers, MD, FAAN, speaks with James E. Galvin, MD, MPH, author of the article “Lewy Body Dementia,” in the Continuum December 2024 Dementia issue. Dr. Weathers is a Continuum® Audio interviewer associate chief medical information officer at the Cleveland Clinic in Cleveland, Ohio. Dr. Galvin is a professor of neurology at the University of Miami Miller School of Medicine in Miami, Florida. Additional Resources Read the article: Lewy Body Dementia Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Weathers: This is Dr Allison Weathers. Today I'm interviewing Dr James Galvin, author of Lewy body dementias from the December 2024 Continuum issue on dementia. Welcome to the podcast, Dr Galvin. Please introduce yourself to our audience.  Dr Galvin: Thank you, Allison. My name is Jim Galvin. I'm a neurologist, a professor of neurology at the University of Miami Miller School of Medicine. Dr Weathers: We're so happy to have you with me today. Thanks, Jim, for your time. And as you highlight right from the start in your really outstanding and comprehensive overview of this really complex topic, even though Lewy body dementia is the second most common cause of neurodegenerative dementia, it often goes unrecognized in clinical practice, resulting in really potentially lengthy diagnostic delays. So, this is a really important article for a neurologist and an important topic for our listeners. So, I'm thrilled we're having this conversation today. While I traditionally start by asking the authors what they feel is the most important clinical message of their article, I would love to actually start a step earlier in this conversation with you. Can you start us off by explaining what's actually meant when we say Lewy body dementia? Dr Galvin: Great. So, you know, I think this is a, this is an interesting concept. So, we're really talking about two diseases that have a shared common pathology. So, Parkinson's sees dementia and dementia with Lewy bodies. So, their shared pathology is a Lewy body and that's why they're often grouped together as the Lewy body dementias. And then there's arguments back and forth as to whether these are distinct diseases or sort of two ends of the same candle burning in different directions. So, Parkinson's dementia is a lot like what it sounds like. So, if someone has Parkinson's disease, then at some point later they develop a dementia. And so back in the 1800's when Parkinson's disease was like first described as an entity, we basically felt that cognition wasn't affected. But we now know that's not true. And so most patients with Parkinson's do have some cognitive symptoms and a large proportion of them will eventually develop dementia. Perhaps up to 80% of Parkinson's patients will develop a dementia. The flip side is the dementia with Lewy body picture. And these are people who present primarily with a cognitive behavioral syndrome that may or may not have parkinsonism. So, they will sometimes have bradykinesia. They rarely have a rest tremor. And so, these are the people that are very much in the delayed diagnosis group. The Parkinson's dementia is more whether the clinician is checking their cognition as part of their annual visit. The flip side is that the people with DLB are often misdiagnosed early on, but together, this is Lewy body dementia, which is the most common disease that many people have never heard of. Dr Weathers: That's a great tagline, I think, for the whole article and for this concept. So now that that we're all on the same page about what's meant when we use that the term, what would you want our listeners to walk away with as their one key takeaway from our conversation today? Dr Galvin: Well, I think the article makes several key points, but I think if I put those all together into a single key point, it would really be that the Lewy body dementias are underrecognized, they're underdiagnosed, yet it is very possible to make the diagnosis using the standardized clinical criteria. They're very, very, very specific. They lack a little bit in sensitivity. So, because other diseases sometimes can look like this, but they're really quite specific. So, if you're confident clinically that the person has Lewy body dementia, you're probably going to be right. And in today's world, we have tests available to help confirm our diagnosis. The world is changing. We can make these diagnosed with much more confidence and we have confirmatory diagnosis laboratory tests that can help us. Dr Weathers: I want to talk more about the diagnosis in one minute, but first, how common actually are dementia with Lewy bodies and Parkinson's disease dementia? Dr Galvin: That's a great question. I think one of the challenges, of course, we really don't know how many people have any disease because it's going to largely rely on how well people code the diseases in the medical record. So, if you look at the most common cause of dementia in the United States, it's really dementia not otherwise specified, right? But we believe it to be the second most common cause of dementia. The Lewy Body Dementia Association, about a decade ago, started to try to develop some estimates. So, we have an estimate about how many people roughly have Parkinson's disease and that about 80% of those individuals would go on to develop dementia. And we know from the dementia population that about 40% of those individuals coming to autopsy have Lewy bodies. So, when you start to put that all together, you can get a reasonable estimate of how many people likely have the disease. And then that can be expanded on an annual basis, just like the Alzheimer's Association uses, by extrapolating those estimates onto the census data. So, we estimate right now there are about 1.4 to 1.6 million Americans who are living with Lewy body dementia. That's less than the 6.8 million people who have Alzheimer's disease, but more than a lot of other common diseases. So, if you think about, again, I said before, it's the most common disease no one's ever heard of. You know, there are about a million people who have multiple sclerosis. There are about eight hundred thousand people who have a stroke. There are about seven hundred thousand people who have a brain tumor. There are two hundred and fifty thousand people who have muscular dystrophy. There are twelve thousand people who have ALS. But I think if you stopped clinicians or people in the street and say have you ever heard of ALS or muscular dystrophy, they would say yes. If you ask them if they've heard of Lewy body dementia, they would say no.  Dr Weathers: That's an excellent point. And I know over the years I think there's been some increased awareness. I think sadly with some of the celebrities that have been impacted, I think that did a lot to raise awareness. But I think you're right that it's still so less commonly recognized by the lay public, by non-neurologists, than so many other diseases that you mentioned. And I think that leads back well into my next question into something that we've already mentioned just a few times already in our short conversation, this unfortunate and very common delay in the diagnosis. Why? And you mentioned earlier that there are these, you know, clinical criteria, these now ancillary tests. So, what makes the diagnosis so challenging? What aspects in particular do you think that neurologists find to be the most challenging in diagnosing patients? What trips us up?  Dr Galvin: So, there's an old analogy, right, that, you know, if you'll be three blind men to an elephant and each of them are touching a different part of the elephant, they'll each think it's something different. So because Lewy body dementia has so many different diverse kind of symptoms, it would really depend on who's seeing the patient first. So, if a person presents predominantly with a memory cognitive disorder and they go see someone who specializes in memory disorders, they're highly likely to be called Alzheimer's disease. If they present predominantly with the movement problem, they're going to see a movement disorder person and be called Parkinson's disease. If they present with a behavioral disorder, they're going to go see a psychiatrist. Then they'll get diagnoses like, you know, geriatric schizophrenia or bipolar disease or major depressive disorder. If they present with the constitutional symptoms, which are very common and drive patients absolutely batty. So chronic constipation, REM sleep disorder, runny nose, you know, heat intolerance, urinary frequency, obstipation, and you know, they're going to be called all sorts of things. So, if you start thinking about this, who do you show up with first is going to guide how fast you can get a diagnosis. So, we interviewed at point over a thousand caregivers and what we found was there was about an eighteen month delay after seeing five to six doctors for the majority of patients, of which Lewy body dementia was misdiagnosed about 75% of the time for the initial diagnosis.  Dr Weathers: Wow, what a sobering statistic. And you spoke about the criteria and some of the ancillary tests. What can really help, do you think, kind of mitigate or prevent this misdiagnosis? What is your approach in your own patients?  Dr Galvin: Well, I think like every good clinician, not starting off with a preconceived notion of what the person has and trying to collect all the valuable information. So, one of the things I highlighted in the article was, while there are diagnostic criteria and people can follow diagnostic criteria, the truth is at your fingertips. You don't always sit and think about whether someone meets diagnostic criteria. So, in the first table in the article, we tried to really then put all the different common symptoms into buckets, right? Because people present like that. They say, well, I have this and I have this and I have this and I have this. Well, then you can start to think about, well, they have a cognitive symptom that's predominantly executive attention or visual perceptual in nature. And gee, they have constipation and heat intolerance and they say they can't smell quite as well as they once did, right, and they're having some disturbance in their sleep with excessive daytime sleepiness. Now you can start to say, well, even though that didn't fit the core and suggestive criteria, the fact is that spectrum of symptoms makes it much easier to begin to make a diagnosis. And so, it's investigative work. A lot of neurology is still investigative work. The old days, they used to say, we knew everything but could do nothing, but now we know everything and can do something about it. And so, I think it's really important that we try to apply this information in clinically useful ways. That was part of the gist of putting this Continuum article together was to try to present it not just as listing the diagnostic criteria, because you can get that anywhere, but how do you actually apply it in clinical practice? Dr Weathers: That's a great point. And that table that you referenced was really fantastic. And I know I say this a lot, but they're true. So, you know, many of the tables, the reference to Continuum, one I will certainly kind of come back to again, again, as an excellent point of care tool. So, I know in, in preparing for today and reading more about, about you and your areas of research that one of your particular areas of focus and expertise is in healthcare disparities, especially in the early detection of neurodegenerative dementias. What is the greatest inequity or disparity that you see in the diagnosis and treatment of patients with Lewy body dementia?  Dr Galvin: So, there's a couple things that are that are really interesting. So first, unlike Alzheimer's disease, which tends to be a little bit more female predominant, the Lewy body dementias are male predominant. It's about 1.6 men for everyone woman. So, it's going to be a different presentation. It's going to be largely men and their caregivers are largely going to be their spouses. So, you're going to see sort of a different person looking, you know, staring on the other side of the table to you. It's going to be largely a male. And the other thing that's really interesting is that almost all of the series, case series, case reports, clinical papers are in predominantly white populations. So, this lends to some interesting things. So, you know, is the disease less common in African Americans and other minority populations or are we just really bad at ascertaining the disease? You know, many of the case reports in Alzheimer's disease include African Americans. In fact, we know that African Americans may be at a twofold increased risk of developing Alzheimer's disease compared to nonHispanic whites, probably due to vascular risk factors. But in case series of Lewy body dementia, almost all the patients are non-Hispanic white. There also seems to be a higher risk in Asian populations, and in fact, some of the very earliest case reports were from Japan. Is this a case ascertainment problem or is this really a disparity in how the disease presents? And I think those are really important questions that still need to be asked. I know as researchers, we struggle to try to develop cohorts that could help us understand that. I would say in my twenty five years of seeing these patients, I would say the large percentage of them, and I've seen a lot of them, have been no-Hispanic white.  Dr Weathers: So, so definitely more research needed in this very important area. So, moving on to somewhat of a personal question, I always, this is such an honor. I always talk about that I get to have this time to sit down with the authors of these outstanding articles and learn not only more about their subjects, but about them as people. I had shared during my last interview that my paternal grandmother had Alzheimer's disease, and unfortunately also my maternal grandmother actually did as well. In preparing for this, I had listened to one of your previous interviews and learned that you also have a personal connection that led you to this subspecialty with several family members impacted. How has this connection inspired your research and your interactions with your patients?  Dr Galvin: Yeah, I mean, so my personal connection was that my maternal grandfather had Lewy body dementia. So, I grew up in a two family home in New Jersey. My grandparents lived on the second floor. We lived on the first floor. I wass very close to my grandparents. I'm still close to my grandmother, who's a hundred and three years old. But when I was a high junior in high school, my grandfather was driving me home from a swimming practice. I was thinner, fitter and more athletic at that point in my life, and he made the world 's slowest left hand turn and we were broadsided. So luckily no one was hurt. But I remember because I was sixteen at the time and just learning how to drive us, Grandpa, what happened? And he's like, oh, the car didn't react. Or, you know, he was blaming the car. And I didn't think much of it because, you know, I was sixteen years old. Sometime after that he was at work, and he was a greaser. So, he would climb through the machines at Colgate Palmolive and keep them all moving. And so, he was at work and he fell off a ladder and then broke his ribs. And in the emergency room, when my grandmother went to pick him up, the ER doctor turned to her and said, how long has your husband had Parkinson's disease? And she's like, what are you talking about? And then that was the first time that all of us had noticed his rest tremor. And the reason he turned the wheel so slow is because he was Bradykinetic. And so then over the next few years, he progressed in his motor symptoms. And then as I got into college, he developed the cognitive symptoms. And so, by the time I had finished medical school that was doing my residency, he was no longer oriented to time. So that even though I had finished medical school, I was in my neurology residency, I was married and with children, I was still in college at that time for him. So, he would always ask me, you know, have I heard anything from getting to medical school and the like. So, I got to watch this person who I grew up with go through all of the different stages of disease. And then eventually he developed lots of hallucinations. And although he was relatively immobile, he experienced a hallucination and jumped out of his chair, fell down, and broke his hip. And so, he underwent a hip replacement, being rather severely demented, and then passed away in the rehab hospital. As I was living this with my grandparents, the one thing that my grandfather, while he could still communicate, and that my grandmother continued to say to me, you know, up until fairly recently was, you know, what are you going to do about this? You know, we're counting on you to make a difference. And so, a lot of my research is really focused on how I can make a difference for people. One, to make sure they get diagnosed properly. Two that we would have something to offer the patient and the family. And three, we can provide hope that we are actually going to come away with effective treatments to make a difference in their lives. Dr Weathers: Well, that is really inspiring. And I think you have really done that in your work. I always like to end these conversations on a hopeful note. So, what are the developments that are on the horizon in terms of diagnosis and treatment of Lewy body dementia that you are most excited about?  Dr Galvin: Well, I think there are three things that are of great interest right now. I mean, there's lots of things, but I think three things of great interest are, one, on the diagnostic side is that we now have assays that allow us to assess synuclein in body fluids and body tissues. So, we can measure synuclein seeding assays in the spinal fluid and we can visualize Lewy bodies through skin biopsies. And that's a tremendous advance because we were really, really limited otherwise to using indirect evidence, and the only indirect evidence we had was abnormalities on DAT scanning. So, we're looking at dopamine deficiencies. But as I mentioned earlier, that's very abnormal in Parkinson's disease. But in dementia with Lewy bodies, it's a little more subtle. So, the extent of dopamine degeneration in- particularly in early DLB is limited. So, you have to look very carefully. If we're not doing quantitative DAT scan imaging, then you may miss those subtle changes. So, I think that being able to directly visualize either synuclein seeding or synuclein aggregation has really changed the game. Plasma assays, blood-based biomarkers are probably a little farther away because they're- the red blood cells have a lot of synuclein and so it interferes with the ability to get a good sensitive assay. But I do think in the next couple of years we will see PET ligands that also bind  synnuclein. So, I think diagnostically we're going to be able to provide better, earlier, and more precise diagnoses. From a treatment perspective, traditionally we've just borrowed medicines from other fields to treat symptoms, but there are a number of disease-modifying trials that are ongoing. I was fortunate to be the academic PI on two very large NIH grants where we test tested disease modifying medicines. Both of those studies are fully recruited and we should get a readout toward the end of 2024 or the beginning of 2025. So very, very excited about that. I also am fortunate to be MPI an NIH grant where we're just going to be testing the first inhuman synuclein vaccine. So very, very excited about the potential to offer disease-modifying medicines and to fulfill the promise that I made to my grandma and grandpa twenty years ago. And I think the third thing is that right now there's a little bit of like an emerging controversy about developing some integrated staging paradigms between the movement disorder world and the cognitive world. And so, while those paradigms are currently published, you know, not everybody agrees with them. But I think whether I like that staging paradigm now or not, the fact that we're coming together and trying to develop some unified staging paradigms, I think, is going to make a big difference in increasing the ability for clinicians to make early diagnoses that are more precise so that we can either get people into clinical trials or into clinical treatment protocols at the earliest possible time. And that's going to make all the difference in the world for the patients and their families.  Dr Weathers: I think that was a fantastic answer. Really, all really exciting things that I think are all, I normally, I say on the horizon. I'm thinking, you know, pretty far ahead. And I think the really wonderful thing is that all of these are either here now or very, very close to being here. So, definitely a very positive way to end this discussion. Well, Jim, thank you so much for taking the time to speak with me today. Dr Galvin: Thank you. This was wonderful. I hope the listeners found this enjoyable and interesting and read the Continuum issue. I think it's going to be the latest and greatest on what we know about the dementias.  Dr Weathers: Again, thank you again, Dr Galvin, for joining me on Continuum Audio. Again, today I've been reviewing Dr James Galvin, his article on the Lewy body dementias, dementia with Lewy bodies, and Parkinson's disease dementia appears in the December 2024 Continuum issue on dementia. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

Send us a textYou will enjoy our conversation with Robert who discusses his high School career where he overcame almost being paralyzed from the waste down and being recruited to Arizona State and later drafted to the NFL. Robert also discusses how he maintained a positive attitude and got recruited at Fort Pierce Central High School in Florida which was a talent pool for the many players to fulfill their NFL dreams.   We also discuss how his brother Clarence made the New England Patriots in a story that many Patriots fans have not heard. Don't want to give it all away many more great stories told by Robert!  Hope you all enjoy and thank you all for listening! 

What if the secret to unlocking student success lies in their ability to self-regulate? In this energizing episode of Aspire to Lead, we welcome back Mitch Weathers, the brilliant author and CEO of Organized Binder, to uncover the powerful link between student regulation and executive functioning. Mitch shares game-changing insights and practical strategies to help students master focus, time management, and self-control—skills that serve as the foundation for both academic achievement and life-long success. Tune in for a conversation filled with innovative ideas, empowering stories, and tools you can bring straight into your classroom! About Mitch Weathers: Mitch became a gifted teacher because he was a mediocre student.  Mitch rarely felt comfortable in the classroom. In fact, it took him 7 years for him to graduate from college.  Choosing to become a teacher, Mitch was fortunate enough to experience school as if it was happening all around him. He was unsure how to jump into his learning with confidence. There is a loneliness to experiencing your education as a passive object as opposed to an active subject.  From the moment he entered the classroom Mitch relied on his personal experiences as a learner. He recognized that what we teach, the content or curriculum, is secondary. We must first lay the foundation for learning before we can get to teaching.  Mitch designed Organized Binder to empower teachers with a simple but research-backed strategy to teach students executive functioning skills while protecting the time needed for content instruction. The secret is found in establishing a predictable learning routine that serves to foster safer learning spaces. When students get practice with executive functions by virtue we set them up for success.   Follow Mitch Weathers: Website: www.organizedbinder.com  Twitter: https://twitter.com/organizedbinder  Instagram: https://www.instagram.com/organizedbinder/  Facebook: https://www.facebook.com/organizedbinder  Linkedin: https://www.linkedin.com/in/mitchweathers/  Vimeo OB showcase: https://vimeo.com/showcase/8775721  ...

Minutes after the Tigers' Senior Day triumph over their Battle Line Rivalry foe, Bradford Bruns provides a live recap from snowy Faurot Field in Columbia. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Minutes after the Tigers' Senior Day triumph over their Battle Line Rivalry foe, Bradford Bruns provides a live recap from snowy Faurot Field in Columbia. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to another exciting episode of the Chef's PSA Podcast! This time, André Natera is joined by Chef Brent Weathers, the entertaining force behind 'Brent Eats Food'. Known for his humorous takes on kitchen life and his vibrant online presence, Chef Brent offers a mix of laughter, honest truths, and personal insights from the world of culinary arts. What You'll Learn in This Episode: Kitchen Etiquette: Dive into the kitchen do's and don'ts that every aspiring chef should know. Social Media Realities: Explore the ups and downs of being a content creator in the culinary space, and the struggles of dealing with online trolls and haters. Hip-Hop Meets Culinary Creativity: Discover how hip-hop culture inspires Chef Brent's creativity in the kitchen and helps him connect to his roots. Humor and Authenticity: Get the lowdown on the viral persona "Fancy Chef" and find out whether it's real or just a clever troll. Classic Cookbooks and Humility: Learn why classic cookbooks still matter, and why staying humble in the kitchen is crucial to success. This episode is a mix of laughter, insight, and valuable lessons—perfect for those who love the mix of food, culture, and creativity that makes the culinary world so dynamic. Subscribe to my Substack! https://chefspsa.substack.com/ Visit Chef's PSA for Books, Free eBooks, and More! https://chefspsa.com/ Shop Chef's PSA Merch! https://shop.chefspsa.com/

Lexington Police Chief Lawrence Weathers joins Jack in the studio to take your calls and comments on recent shootings downtown, the benefits of the Flock cameras, and more on #LEX.  See omnystudio.com/listener for privacy information.

Opioids may be considered for temporary use in patients with severe pain related to selected neuropathic pain conditions and only as part of a multimodal treatment regimen. Close follow-up when initiating or adjusting opioid therapy and frequent reevaluation during long-term opioid therapy is required. In this episode, Allison Weathers, MD, FAAN speaks with Friedhelm Sandbrink, MD, FAAN, an author of the article “Opioids and Cannabinoids in Neurology Practice,” in the Continuum® October 2024 Pain Management in Neurology issue. Dr. Weathers is a Continuum Audio interviewer and the associate chief medical information officer at the Cleveland Clinic in Cleveland, Ohio. Dr. Sandbrink is the national program director of Pain Management, Opioid Safety and Prescription Drug Monitoring Programs at the Veterans Health Administration, Uniformed Services University in Bethesda, Maryland. Additional Resources Read the article: Opioids and Cannabinoids in Neurology Practice Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media @ContinuumAAN facebook.com/continuumcme Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum Journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal and how to get CME. Dr Weathers: I'm Dr Allison Weathers. Today I'm interviewing Dr Friedhelm Sandbrink, who is one of the authors of the article Opioids and Cannabinoids for the Practicing Neurologist from the October 2024 Continuum issue on pain management Neurology. Welcome to the podcast and please introduce yourself to our audience.  Dr Sandbrink: Yeah, hi. So, I'm Friedhelm Sandbrink. I'm a neurologist and pain physician. I work at the Washington DC VA Medical Center, where I lead our intercessory pain management team, and I have a role also in the VA central office for pain management. I'm also associate professor, clinical associate professor at George Washington University and at the Uniformed Services University in Bethesda.  Dr Weathers: A lot of expertise, which you obviously brought to this article. And I do want to emphasize before we get started, although the article discusses both opioids and cannabinoids, as I said in the introduction, you worked in specifically on opioids. And so that's the part of the article where we'll focus our conversation today. Of course, I think all of our Continuum Audio topics are really fascinating. I know that some may not resonate as much, especially with our non-neurology listeners as others. Clearly not the case with your articles. I was reading it and preparing for a conversation today. I was really struck by how broadly applicable this topic is, not only to all neurologists but, really, all physicians, and even it should be to all of our listeners. Especially with what happened been going on over the last several years, what's been in the news about the opioid epidemic. And while usually like to start with this question, it feels even more pertinent in your case, what is the most important clinical message of your article? Dr Sandbrink: So, the role of the opioid, the role of opioid therapy, really, for pain care has changed dramatically over the last many years right? I mean, it's we, we still consider opioids like the most potent analgesic medication for treatment of acute pain. The benefit for chronic pain really has changed right I mean, you know, we- the understanding in that regard and they're controversial. So, they're generally not recommended for chronic treatment for neuropathic pain conditions or for headache, but there are probably situations when opioids are still indicated and may be considered especially for temporary use. So, one example is probably the patient who has severe acute post hepatic neuralgia and we know that we use other medications for that, you know, the gabapentinoids and duloxetine and but they may take several days or weeks to work, right? And we have to titrate them up. And when more acute pain relief is needed, the opioid medication may be may be an option for temporary use. But I think what we need to keep in mind is that when we use it, we need to be informed about how to mitigate the risks, right? What, what are our best ways to reduce harms? And we need to also know the regulatory, you know, situation right I mean, what is that that we have to do nowadays to stay within the frameworks, right? And so, one of the main emphasis on this article is really go through what the clinical that the CDC has now established as the standards for opiate therapy when we use opioids I think we all need to know the rules right I mean, we know what to do to mitigate risks. What is expected from us in regard to use it as safely as possible, right? And that's important for the patient. That's also important for us in our practice.  Dr Weathers: I think very important advice. And this seems so obvious, but at the same time, I think it's worth very clearly stating why is it so important for neurology clinicians and again, really all clinicians, to read this article? Dr Sandbrink: Yeah. We need to know the words regarding opiate prescribing right in the clinic. You know, the CDC has now issued their opiate practice guide, the Opiate Therapy Guideline. Really, it's a guideline for pain care in 2022. It's an update from 2016 that made some major changes in that regard. And I think we need to know really where we are nowadays in regard to expectations. I think we need to place the opiate therapy appropriately in our armamentarium regarding the many options that we have for pain care. But then when we use them, we need to know what we need to do to make it safe. Right? So, I'm thinking about the prescription drug monitoring programs and the patient education that's expected. We use in our practice an informed consent process even for patients on chronic pain, When and how to interpret urine drug screens, right? And how to issue, and maybe when to issue a naloxone comedication in order to have a rescue medication in case the patient is in a terrible situation. So, these are just things that have become nowadays standards of care and part of our practice. And we need to be familiar with it and use them as we take care of the patients. And for instance, in regard to opiate medication, we need to know about the specific rules regarding telehealth, prescribing of controlled substances, controlled Substances Act and the Ryan Hate Act that mandates in person evaluations for patients when we prescribe controlled substances. That obviously has been somewhat amended or changed or temporarily put on hold during the COVID crisis. And many states now have started developing their own guidance in regard to what's available and what's possible during telehealth. And we need to be familiar about that also.  Dr Weathers: I think those are such important and thoughtful points. I, I've mentioned it several times on this podcast before. I am a clinical informaticist and this is a topic that really lends itself to the EHR being able to help support. So, a lot of the things that you just mentioned, the consents for patients, the prescribing of naloxone, some of the support, clinical decision support can really be done in the electronic health record to help support providers. However, it's also one of those things where if people don't understand what's behind it, it can become a little bit of a crutch. And so, as I was reading the article, I was really struck by how helpful it is to really have that background. I think people can become very dependent and it becomes almost just doing it all for them and, and they lose the- then you can make this argument about probably a lot of the other clinical decision supports in there, but really understanding the why behind a lot of the support that's there around all of the, the tools that are in there to, to support safe opioid prescribing. I think it's so important for that people have that background that the article provides.  Dr Sandbrink: I think often it feels like you're going through a checklist of things to do right and, and, and you do right. But at the same time, as you said, you need to know why you're doing it right And, and I think it's very important for us to know what the rules are and the expectations in regard to standards of care. So, we also know what is the framework that we have to follow, but where can we make modifications? Where can we individualize based on the patient's need? What is really that that is still within our ability to do and how to modify that? Because in the very end, it really is about good care of the patient. We need to know what we are allowed to do, but we also need to know where the limits are right And I hope that that article provides really some information about that, especially as it outlines what the CDC expects. But then also, I think it gives - hopefully, and this is a message that the CDC also has – it really emphasizes that it's about good communication with the patient, truly informing them and about what are the range of options and the limits that we have, but also at the same time never to abandon the patient. You know, I think this is something that we need to understand. It's not really about us. The rules are there to make the care of the patients safer. The rules are not the primary goal itself. It is still patient care. So, in that regard, we need to make sure to never abandon the patient, even if the patient for instance, may come to us and maybe they took more opiates and prescribed or you know, and they ran out early and figure out what exactly was that drove the patient for that, right? I mean, you know, so that we know maybe it is actually worse than pain. Maybe there was something that happened that caused the patient to have a significant increase of it. You know, I think one of the biggest misconceptions is really also that patients who make sure some misuse of medication, that everybody has opioid abuse disorder, addiction. Common, far too common, right? And I think we've learned over the years how common it is. Clearly pain itself, intractable pain is a very strong driver of behavior. If you're in pain, if a patient is in pain, they are desperate often to seek some kind of relief. And taking extra medication in itself, while it's not at all something that we can endorse and tolerate, obviously in many ways, right, we have to still take it as a possible sign of pain control rather than opiate use disorder in itself. So, we need to be very careful of how to assess such a patient and that we guide them into the right direction in regard to the next.  Dr Weathers: That, again, is very important advice, and thinking about how chronic pain on a very different level than acute pain, right? Understanding how these patients are processing pain in a very different way than patients with acute pain. And again, also, I think a very important point that the pendulum has swung kind of back and forth over the years. You know, that they were in pain was another vital sign and it was make sure you're asking your patient about pain. And then all of a sudden it was, oh, we have to be really careful and people should not, nobody should be on these medications, which you- to your point, led to sudden abandonment. And that's not the point. That's not what we should be doing as providers. I know, though, there's very sensitive and challenging situations when you find out a patient though, perhaps taking more than expected because of chronic pain, but perhaps diversion. How have you handled those challenging cases? Dr Sandbrink: I think diversion needs to be taken obviously very, very seriously. And you know, if a patient is truly diverting medication and there are obviously multiple variations of that, right? I mean, it's like giving it to a family member, for instance. That's one thing. It's on the other hand actually selling it. I think a patient who diverts is such a situation where opioid prescribing has to stop immediately, right? I mean, this is not a patient that we would take off at this point. I mean, so I think it's one of the very, very few occasions where you'd say that you have to just stop it immediately. I think there are other situations really in general, I think the patients who have been on opioids long term, especially in higher doses, I mean the majority of patients are not different. We have to be aware of it. We have to always look out for it. That's part of our risk mitigation. But we also have to make sure that patients on long term opioid therapy, right, that we guide them appropriately. I think the guidance probably in many ways is that we want to make sure whether opioids, the opioid medications still have helps them to achieve their functional goal. Are they truly helpful for the patients in achieving what they aspire to do in regard to their work life, in regard to the family situation. I think a lot of times for patients who have been on opioids long term, it's probably not that it really helps them that much for pain anymore, but they've often made that experience and they try to stop it. Pain gets worse, which is the effect obviously, that that happens with opiates right I mean, the moment you stop them, the opposite of the effect happens right I mean, they become irritable, right? The sleep gets worse, the pain gets worse, right? And it's a temporary phenomenon. And so, when we try to talk to a patient about possibly reducing the medication, I think this is one of the most challenging aspects that we have, that we really look at the patient and try to motivate them to be part of that plan. It's not something that we want to impose on the patient, but rather that we motivate the patient to look towards in the long term, probably more efficient pain care, which is really much more comprehensive pain care using all modalities. And I think one of the things that we learned over the last years is that when we make opiate medication reductions, we have to go very slowly. I think in the past we've talked about a matter of weeks and now the guidance including from the CDC guideline is probably more- closer to 10% per month to reducing it. So, you make reductions that may take many months to a year even, right. And the patient is allowed to help us, guide us how fast we can go. And you're allowed to make pauses if needed for the patient to adjust physiologically to reduction. And we want to go slowly enough that we don't run into an acute withdrawal situation right If you do it very gradually, it's much more manageable for the patient to do that. Then they'll be much more motivated to work with you. But still, it's a challenge right I think that we do. And I think at the very end, it's really providing good patient care that allows us to build that rapport with the patient that they trust us and that they say, Hey, you know, yes, I'm, I'm willing to work with you, doc, to maybe reduce my reliance on the medication, right? So that that I don't end up on this. You know, one of the things that I sometimes do is asking patients when they come to us this first time and there are a lot of opiate medication maybe is like, what's your goal in this regard? Where do you see yourself in, in five or ten years? Are you thinking you will still be on this medication or would you want to come off? And how can we help you then if that's your goal? So, I think this is all part of our important conversation that we have to have in order to motivate the patient.  Dr Weathers: What I heard you say repeatedly through that. And what I really want to emphasize for our listeners is that the therapeutic relationship with that patient that no matter what that scenario, really keeping them and their goals at the focus and really making it a partnership, not a paternalistic relationship, not dictating to them what the plan will be, but really emphasizing shared decision-making. And I think again, that's such a key take home point for our listeners. And also, even going back to my original question about diversion, what really struck me in your response is even though you said yes, then that was one of the few cases or perhaps even the only case where you said, all right, this is where we have to cut it off immediately. It still wasn't abandoning them as a patient, although you said we have to stop the medication. It wasn't about ending that relationship with that patient necessarily, but ending that therapy option. So really critical in how we think about opioids therapy and our relationship overall with patients.  Dr Sandbrink: So, Allison, maybe I can add on, you know, I think the patient with diversion is the one aspect where we have to look at the population as a whole and the opioid that makes it to somebody else, potentially a vulnerable child, right, even you know, who could die from it, right? Another aspect of probably the patients we mentioned them earlier who have opioid use disorder, who maybe take more than prescribed and where we as a neurologist feel often quite uncomfortable dealing with that. And I think that's so important that at that point we don't abandoned the patient, right. I mean, you know, maybe we want to continue, we don't want to continue the opiate medication for the treatment of the pain. But as we diagnose and initially suspect opiate use disorder and have a conversation about it with a patient, we need to guide them to therapy. It's a treatable condition, right? It's an untreated, it's, it's actually rather lethal in many situations, right? So, we have to make sure that we provide an integrated access to the treatment or we have a warm hand off to somebody who will continue that and not abandon the patient in regard to that pain care, as we said earlier also, right? I mean, because that second condition really doesn't obviously I mean in any way that the pain is any better. No, I mean it's a common concurrent situation and we need to make sure that they still have the better pain care possible. Dr Weathers: Again, it's a really key point for our listeners as and as I emphasized at the beginning, regardless of their subspecialty or specialty or even if they're physicians, I hope for everybody listening they can take away something from this. How did you become interested in pain management? I know that this was something that that you became interested in even when still in training. What struck you about this? Dr Sandbrink: So, yeah, so my initial fellowship actually after residence was clinical neurophysiology. So, you know, a lot of the spine and different nerve conditions really was, was, but then when I began practice, clearly longitudinal care, chronic disease management, I think many of us in neurology do that right That, that became an emphasis. And I think building that accord with the patients right and, and, and that having that ability to provide pain care is something that really worked out very well. I think I love teamwork and part of teamwork pain care in in our setting is a collaborative approach right You have other disciplines, physical therapist, psychologist, right? You know, you have intervention and nonintervention provider. I think nowadays we even have integrative modalities available to us. So, I'm working together on a team, trying to optimize it here with many team members that we have with everybody bringing that personal expertise is something that I really cherish. Dr Weathers: I feel like that's such a great example and I feel like a lot of people don't necessarily think about this specialty as one that is, that is collaborative in that way. And it really is. So, I, I think that's a wonderful way to highlight it. I always like to end on a hopeful note. And I know that there hasn't been necessarily a lot of hope or positive news in regards to, to opioid use, opioid therapy in the last several years. But are there developments that give you hope that you're excited about?  Dr Sandbrink: So, you know, I think there are probably two things I would mention. On one hand, I think patients are so much more aware now about the risk of opioids. So that is actually much easier to look and get them motivated about comprehensive pain care. There's much more interest in integrative modalities. Patients nowadays would be much more willing to maybe try acupuncture or mindfulness or yoga or Tai chi. So, I think that's actually a really nice development in that regard. But if I think about opioids specifically, I think the availability of buprenorphine as a medication, it's certainly something we should mention in this interview here, right? I mean, buprenorphine is now increasingly used for pain as well, not just in the higher dosage for opiate use disorder. It really is a good choice for patients who have. pain conditions, chronic pain conditions, severe pain and to require a daily opioid, especially in regard to safety aspect when the patient has medical conditions or mental health conditions that may put them at higher risk and they have to be on an opiate anyway. This is really something that I think has changed our practice. As you know, we don't have to rely on the X waiver anymore. Anybody with a DA license can prescribe buprenorphine. Even for opiate disuse disorder, it really has become something that I think many of us integrate much more into our practice and I want to encourage the listener to really look into that direction.  Dr Weathers: Excellent advice and I'll actually refer our listeners who are subscribers of Continuum to reference, specifically, Table 4 where you dive into the buprenorphine. It's just a fantastic table, as are all the tables. It really goes into detail of the commonly prescribed opioids for pain with the special characteristics and the conversion of morphine equivalent, but especially for this one about how to prescribe the details of us. Again, when I was preparing for this, I said wow. Like for me as a neurohospitalist and thinking about when I'm on service, how to use it, when to use it, I thought it was incredibly useful for that management of patients, especially as a powerful point of care tool. Well, thank you so much for being here with me today for this great conversation.  Dr Sandbrink: Yeah, thank you. That was my pleasure. Dr Weathers: Again, today I've been interviewing Dr Friedhelm Sandbrink, whose article on opioids and cannabinoids for the practicing neurologist, written with Dr Nathaniel Schuster, appears in the most recent issue of Continuum on Pain Management and Neurology. To learn more about the topics of opioids and cannabinoids, be sure to read the full article. And don't forget to listen to Continuum audio episodes from this and other issues. Thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

Could Verstappen's comeback victory in Brazil be the greatest in F1 history? Does Lando Norris possess the mental toughness required to become a world champion? Is Alpine now a serious contender for a top spot on the grid next season? This week, DC and EJ review the dramatic events at the Brazilian Grand Prix, where Max Verstappen delivered a potentially title-winning performance after starting in 17th place.Plus, they were not surprised that Flávio Briatore's Alpine team secured a double podium finish even earlier than he had predicted for 2026 during the podcast in August.Note: This episode was recorded prior to Sauber's announcement that Valtteri Bottas and Zhou Guanyu will not be returning to the team in 2025.Anchors, you can now join the FFS! Club for ad-free listening, bonus episodes and more!Get in touch with DC and Eddie by emailing ffs@whisper.tv and follow the show on Instagram, Twitter, YouTube and TikTok.Produced by WhisperExecutive Production by Whisper & New StrangeRecorded & Edited by New Strange Hosted on Acast. See acast.com/privacy for more information.

Kyleigh Weathers is the creator of Queerly Attached. A business that is dedicated to providing attachment trauma recovery resources for the LGBTQ+ community. Attachment trauma hits different when you're queer. We each have our own experience around societal rejection, parental abandonment and religious trauma. Kylie was raised mormon, caught at 16 with a girlfriend, attempted to pray the gay away, served a mission for her church in 2005 and was sent home from mission because she was a lesbian. Finally peeked out of the closet in 2006. Uhaul and a wife in 2008. So how the hell did she end up married to a man with a son by 2012? Join us as we explore queer identity and attachment and how true healing can occur. This podcast is brought to by Ethical Change Agency. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this special #AspireLead bonus episode, Mitch Weathers, author and creator of Organized Binder, discusses how to rethink traditional goal setting. Together, Josh & Mitch dive into why the old methods of setting goals often fall short and explore practical strategies to make goal setting more effective. Mitch shares real-world examples of how to set achievable goals with students and explains how self-regulation is crucial in the process. Tune in for fresh insights on how to set goals that stick and lead to meaningful progress! About Mitch Weathers: Mitch became a gifted teacher because he was a mediocre student.  Mitch rarely felt comfortable in the classroom. In fact, it took him 7 years for him to graduate from college.  Choosing to become a teacher, Mitch was fortunate enough to experience school as if it was happening all around him. He was unsure how to jump into his learning with confidence. There is a loneliness to experiencing your education as a passive object as opposed to an active subject.  From the moment he entered the classroom Mitch relied on his personal experiences as a learner. He recognized that what we teach, the content or curriculum, is secondary. We must first lay the foundation for learning before we can get to teaching.  Mitch designed Organized Binder to empower teachers with a simple but research-backed strategy to teach students executive functioning skills while protecting the time needed for content instruction. The secret is found in establishing a predictable learning routine that serves to foster safer learning spaces. When students get practice with executive functions by virtue we set them up for success.  Follow Mitch Weathers: Website: www.organizedbinder.com  Twitter: https://twitter.com/organizedbinder  Instagram: https://www.instagram.com/organizedbinder/  Facebook: https://www.facebook.com/organizedbinder  Linkedin: https://www.linkedin.com/in/mitchweathers/  Vimeo OB showcase: https://vimeo.com/showcase/8775721  ...

Tim, Chris Karr (SCNR), Elad (SCNR), and Serge are joined by Seth Weathers to discuss Biden being accused of pooping his pants during a D-Day event in France, Russia threatening to strike French military trainers, Trump saying the campaign has raised nearly $400 million since guilty verdict, & Steve Bannon being ordered to report to prison on July 1st. Hosts:  Tim @Timcast (everywhere)  Chris @ChrisKarr17 (X) Elad @elaadeliahu (X) Serge @sergedotcom (everywhere) Guest: Seth Weathers @sethweathers (X) Learn more about your ad choices. Visit megaphone.fm/adchoices